KC
SNTI icon

Kingfisher Capital’s Senti Biosciences Holdings SNTI Stock Holding History

Kingfisher Capital’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,422
Closed -$248K – 182
2022
Q3 		$248K Buy
11,422
+106
+0.9% +$2.09K 0.07% 155
2022
Q2 		$222K Buy
11,316
+217
+2% +$17.4K 0.06% 153
2022
Q1 		$1.09M Sell
11,099
-69
-0.6% -$6.81K 0.28% 100
2021
Q4 		$1.1M Buy
+11,168
New +$1.11M 0.25% 106

Other funds holding SNTI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
IC
Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Kingfisher Capital's SNTI Position: Q4 2022 in Review

Kingfisher Capital sold out of Senti Biosciences Holdings (SNTI) in Q4 2022, closing a stake of 11,422 shares — an estimated $248K sold.

Kingfisher Capital first reported a position in SNTI in Q4 2021 and held it in 4 quarters. The position peaked at $1.1M in Q4 2021. 26 funds tracked by Wall St. Rank hold SNTI as of Q4 2022.

  • Kingfisher Capital reported no remaining Senti Biosciences Holdings position as of Q4 2022 after selling out during the quarter.
  • Kingfisher Capital sold 11,422 Senti Biosciences Holdings shares in Q4 2022, an estimated $248K.
  • Kingfisher Capital first reported a position in Senti Biosciences Holdings in Q4 2021 and held it in 4 quarters.
  • Kingfisher Capital's Senti Biosciences Holdings position peaked at $1.1M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2022.

Based on Kingfisher Capital's 13F filing for Q4 2022, filed 19 Jan 2023.